title: Treatment results of radical surgery and definitive chemoradiotherapy for patients with submucosal esophageal squamous cell cancinomas.
abstract: BACKGROUND
  A radical esophagectomy with extensive lymph node dissection is the mainstay treatment for submucosal esophageal cancer, though definitive chemoradiotherapy (CRT) has also been applied. However, the treatment outcomes have not yet been extensively investigated.
  
  
  METHODS
  Forty-nine patients with submucocal esophageal squamous cell carcinoma, 24 and 25 of whom had been treated by a radical esophagectomy with extensive lymph node dissection (Surgery group) and definitive CRT using 5-Fluorouracil and CDDP with concurrent radiation of 60 Gy (CRT group), respectively, formed the study cohort.
  
  
  RESULTS
  In the Surgery group, the overall and cause-specific 5-year survival rates were 75.4% and 90.0%, respectively. No operative or hospital deaths had occurred. In the CRT group, a complete response (CR) had been achieved in 22 (88%) patients. The 3- and 5-year overall survival rates were 79.3% and 36.9%, respectively, while the cause-specific 3- and 5-year survival rates were 75.2% and 55. 7%, respectively. No treatment-related deaths had occurred.
  
  
  CONCLUSIONS
  These data suggest that: (i) a radical esophagectomy with extensive lymph node dissection can be a standard treatment offering excellent survival and (ii) a definitive CRT is a reasonable alternative to surgery, especially for patients with complications.
authors.affiliation: Department of Gastroenterological Surgery, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan. ytoh@nk-cc.go.jp
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Toh
authors.forename: Takefumi
authors.initials: T
authors.lastname: Ohga
authors.forename: Shuhei
authors.initials: S
authors.lastname: Itoh
authors.forename: Akira
authors.initials: A
authors.lastname: Kabashima
authors.forename: Kazuharu
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Eisuke
authors.initials: E
authors.lastname: Adachi
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Sakaguchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okamura
authors.forename: Hideki
authors.initials: H
authors.lastname: Hirata
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil